peptides cjc 1295 and ipamorelin CJC-1295 (NO DAC) + – Research Peptide CJC-1295/Ipamorelin - Pure Health Peptides

What Reclassification Would (and Would Not) Change If BPC-157 is moved to Category 1 after the July 2026 meeting, the regulatory impact is narrower than many online summaries suggest: Scenario Category 2 (current default) Category 1 (post-reclassification) FDA approval No No 503A compounding Not permitted Permitted (pending final rulemaking) 503B outsourcing facilities Separate list (503B bulks list) Separate determination required Commercial drug product Not available Still not available without NDA Research/laboratory use Legal for research Legal for research (unchanged) In plain terms: Category 1 status lets a patient with a valid prescription get BPC-157 prepared by a state-licensed compounding pharmacy

Pini LA, Vitale G, Ottani A, Sandrini M

FDA reviewers flagged that the compound nominations did not consistently specify which form was being evaluated

The MR-Base platform supports systematic causal inference across the human phenome